Dual blocking PD-1 and Tim-3 not only on T cells but also on DC, NK cells may achieve better clinical benefit. LB1410 is a recombinant humanized anti-PD-1/TIM-3 bispecific antibody (BsAb) developed by ...

This material on this page is ©2025 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please ...

The regeneration-infiltration step was repeated 3 times. Data analysis 7.0 software was used to analyze the affinity of antibody samples. BLI analysis of the binding activity of YG-003D3 to PD-1/LAG-3 ...

Agenus (AGEN) entered into a License, Development, and Commercialization Agreement with Incyte (INCY), under which Incyte ...

A team of researchers have made a new discovery in the field of hematology, providing an explanation for spontaneous and ...

Over the trailing one-year period, Ariel International (DM/EM) Composite increased +5.98% gross of fees (+5.43% net of fees), ...

Adding the anti-CD20 monoclonal antibody obinutuzumab (Gazyva) to standard therapy for lupus nephritis is more efficacious ...

Natural killer (NK) cells are an intriguing immune cell type in MM given the recent development of monoclonal antibodies (mAbs), elotuzumab (anti-SLAMF7), and daratumumab ... Common IRs include KIRs, ...